Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study

Liver cancer is the second leading cause of cancer-related death worldwide [1]. The majority of primary liver cancer presents as hepatocellular carcinoma (HCC), the incidence of which is rising in many parts of the world [2]. The vast majority of HCC cases occur in the setting of liver cirrhosis, usually because of chronic hepatitis C or hepatitis B viral infections, alcohol consumption, non-alcoholic steatohepatitis, or diabetes [3]. The degree of underlying liver disease, as well as the tumor stage and patients ’ general condition, must therefore be considered when making treatment decisions for HCC.

Source: Journal of Hepatology - July 24, 2016 Category: Gastroenterology Authors: Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao-Ping Chen, Lucy Dagher, Junji Furuse, Jean-Francois H. Geschwind, Laura Ladr ón de Guevara, Christos Papandreou, Tadatoshi Takayama, Arun J. Sanyal, Seung Kew Y Source Type: research